Abstract
Mineralocorticoid-receptor antagonists (MRAs) have been shown to reduce adverse cardiovascular outcomes in high-risk patients with ST-segment elevation myocardial infarction (STEMI). Preliminary data suggest that MRAs might improve natriuretic-peptide profiles in patients with STEMI who do not have heart failure, but their clinical efficacy in this patient population requires further study.